Mesh : Aged Dexamethasone / adverse effects therapeutic use Humans Immunosuppressive Agents / therapeutic use Male Necrobiotic Xanthogranuloma / complications drug therapy immunology pathology Paraproteinemias / complications drug therapy immunology Skin / pathology Thalidomide / adverse effects therapeutic use Treatment Outcome

来  源:   DOI:10.1016/j.clml.2011.03.020   PDF(Sci-hub)

Abstract:
Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-κ type.(1) Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy. We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment.
摘要:
暂无翻译
公众号